| Display title | Medicine:SCAR-Fc |
| Default sort key | SCAR-Fc |
| Page length (in bytes) | 7,634 |
| Namespace ID | 3048 |
| Namespace | Medicine |
| Page ID | 838295 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Sherlock |
| Date of page creation | 23:56, 4 February 2024 |
| Latest editor | imported>Sherlock |
| Date of latest edit | 23:56, 4 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | sCAR-Fc (Soluble Receptor Analogue) is an experimental prophylactic treatment against coxsackievirus B3 (CVB) infections. Coxsackievirus B3 can cause cardiac damage, eventually resulting in a weakened and enlarged heart that is termed dilated cardiomyopathy. While many other treatments inhibit viral... |
